• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [17988 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     NIHR Health Services and Delivery Research programme Evaluating the use of patient experience data to improve the quality of inpatient mental health care
2020     NIHR Health Technology Assessment programme Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2020     National Committee for Technology Incorporation (CONITEC) [Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020     National Committee for Technology Incorporation (CONITEC) [Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2020     NIHR Public Health Research (PHR) programme The effectiveness of promotional campaigns associated with revised UK drinking guidelines: a prospective evaluation
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code] Book V
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Givosiran (acute hepatic porphyria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Venetoclax (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Development of scientific concepts for the generation of routine practice data and their analysis for the benefit assessment of drugs according to §35a Social Code Book V – rapid report]
2020     National Committee for Technology Incorporation (CONITEC) [Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Urinary proteome analysis for detection of diabetic nephropathy in patients with diabetes mellitus and arterial hypertension. Update of Commission D13-01. - Rapid Report]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (metastatic Merkel cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2020     NIHR Health Technology Assessment programme Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020     NIHR Health Technology Assessment programme The Namaste Care intervention to improve the quality of dying for people with advanced dementia living in care homes: a realist review and feasibility study for a cluster randomised controlled trial
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Ceftolozane/tazobactam (acute pyelonephritis) - Benefit assessment according to §35a Social Code Book V
2020     NIHR Health Technology Assessment programme Non-contact infrared thermometers for measuring body temperature in acutely ill children: a method comparison study
2020     NIHR Health Services and Delivery Research programme Effects of increased distance to urgent and emergency care facilities resulting from health services reconfiguration: a systematic review
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cobicistat (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V
2020     Basque Office for Health Technology Assessment (OSTEBA) [Clinical Practice Guidelines on the diagnosis and treatment of non-serious blunt chest trauma]
2020     NIHR Health Technology Assessment programme CARer-ADministration of as-needed sub-cutaneous medication for breakthrough symptoms in home-based dying patients: a UK study (CARiAD)
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid review: alternatives to timolol for the treatment of glaucoma]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Comparative results of the different screening strategies used for T21, T18 and T13: adaptation of the EUnetHTA assessment]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Spyglass® cholangiopancreatoscopy for biliary and pancreatic diseases]
2020     NIHR Health Services and Delivery Research programme Factors influencing the utilisation of free-standing and alongside midwifery units in England: a mixed methods research study
2020     Austrian Institute for Health Technology Assessment (AIHTA) Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with carotid artery disease]
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Leadless pacemaker for right ventricle pacing (Update 2020)
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Precice® intramedullary nail system, with external remote controller, for limb length discrepancy]
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS. Update 2020
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetal neurosonography in suspected central nervous system abnormalities]
2020     Ontario Health Transcatheter Aortic Valve Implantation in Patients With Severe, Symptomatic Aortic Valve Stenosis at Intermediate Surgical Risk: A Health Technology Assessment
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Renal replacement therapies in acute kidney failure]
2020     Ontario Health Portable Normothermic Cardiac Perfusion System in Donation After Cardiocirculatory Death: A Health Technology Assessment
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Intrauterine ultrasound-guided transcervical radiofrequency ablation
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intravascular ultrasound in coronary artery disease]
2020     Center for Drug Evaluation (CDE) The health technology assessment of bipolar TURP, bipolar TUVP (vaporization of the prostate), Green Light TM, thulium, holmium, and diode laser prostatectomy in Taiwan
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Human papilloma virus (HPV) vaccine in patients with HPV lesions or infection]
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Summary: investigation, treatment and follow-up algorithm - lung cancer]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Parenteral infusion pump during general hospital ward]
2020     Ontario Health Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
2020     Scottish Health Technologies Group (SHTG) Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with deep vein thrombosis]
2020     Ontario Health Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer: A Health Technology Assessment
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Statins, lifestyle and dietary interventions to prevent cardiovascular disease]
2020     Scottish Health Technologies Group (SHTG) Pre-treatment DPYD genetic testing for patients who are prescribed chemotherapy involving fluoropyrimidines – SHTG Assessment
2020     Scottish Health Technologies Group (SHTG) Continuous glucose monitoring in pregnant women with type 1 diabetes – SHTG Adaptation
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital tomosynthesis for breast cancer]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Target next generation sequencing-based gene panels in tumors of unknown origin]
2020     Scottish Health Technologies Group (SHTG) Endobronchial valves for lung volume reduction in patients with severe or very severe emphysema - SHTG Recommendation
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Image-guided radiation therapy in liver and lung tumors]
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Health Services Research in Oncology. Part I: End-of-Life Care
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Volumetric modulated arc therapy in patients with lung cancer, prostate cancer, high-risk gliomas and tumors in head and neck]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions, updated in August 2020: administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Pegvaliase in phenylketonuria]
2020     Austrian Institute for Health Technology Assessment (AIHTA) Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 1; Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 2 (Appendix)
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital dermatoscopy for dysplastic nevi]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Somatostatin analogs with lutetium-177 in neuroendocrine tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Ustekinumab in Crohn’s disease]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Ozone therapy]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Radiofrequency ablation in benign bone tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2020     Ontario Health 10-kHz high-frequency spinal cord stimulation for adults with chronic noncancer pain: a health technology assessment
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endoscopic full-thickness resection of colorectal lesions]
2020     Ontario Health Continual Long-Term Physiotherapy After Stroke: A Health Technology Assessment
2020     Austrian Institute for Health Technology Assessment (AIHTA) Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2020     Ontario Health Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults: A Health Technology Assessment
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intra-arterial chemotherapy for retinoblastoma]
2020     Adelaide Health Technology Assessment (AHTA) Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intranasal esketamine for severe resistant major depression]
2020     Ontario Health 5-Aminolevulinic Acid Hydrochloride (5 ALA)–Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment
2020     Adelaide Health Technology Assessment (AHTA) Serious adverse events associated with yellow fever vaccination
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intrathecal baclofen pump in spastic patients]
2020     Ontario Health Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment
2020     Adelaide Health Technology Assessment (AHTA) Serious adverse events associated with oral cholera vaccination
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Endometrial microbiome test in assisted reproduction]
2020     Ontario Health Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Migalastat for Fabry disease]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: safety of switching biologics and their interchangeability]
2020     Health Technology Wales (HTW) The clinical effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis